Market Update (NASDAQ:AMGN): Novartis biosimilar copycat takes aim at Amgen’s drug Enbrel

[Reuters] – The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster Enbrel drug, the Swiss drugmaker said on Friday. Biosimilars . . . → Read More: Market Update (NASDAQ:AMGN): Novartis biosimilar copycat takes aim at Amgen’s drug Enbrel Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s leukemia drug gets conditional European approval Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen pays $71 mln to settle Enbrel, Aranesp marketing case Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.